{"classes":[{"categories":[{"measurements":[{"comment":"Only one event data observed exceeding the median value, and maximum value was censored data, so the upper bound of confidence interval (CI) could not be estimated","groupId":"OG000","lowerLimit":"2.000","upperLimit":"NA","value":"24.10"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"11"}],"units":"Participants"}],"description":"The response duration in participants with an objective response was measured from the date of the first Complete Response or Complete Response unconfirmed or Partial Response to the first date of Relapsed Disease or Progressive Disease (PD). For participants who did not progress during the study, DOR was censored at the last adequate response assessment not showing evidence of PD.","dispersionType":"95% Confidence Interval","groups":[{"description":"Lenalidomide 25 mg administered by mouth (PO) once daily (QD) until progressive disease or unacceptable toxicity","id":"OG000","title":"Lenalidomide"}],"paramType":"NUMBER","populationDescription":"The EE population who had a documented response and consisted of participants who met basic protocol requirements (all eligibility criteria) and were evaluated after receiving at least one dose of lenalidomide","reportingStatus":"POSTED","timeFrame":"From day 1 of study treatment to first documented response; up to data cut-off date of 19 May 2017; Maximum study duration was 134.1 Weeks","title":"Kaplan-Meier Estimate of Duration of Response (DOR) for Responders as Assessed by the ESEC","type":"SECONDARY","unitOfMeasure":"weeks"}